top of page

Day 1 | MONDAY, OCTOBER 10, 2022 | 8:45AM - 7:00PM EDT

Welcome and Introduction to Day 1

Conference Co-Anchors: 
Alexander Fleming, MD, Founder and President of the Kitalys Institute, Executive Chairman of Kinexum 

Joan Mannick, MD, CEO, Tornado Therapeutics
Thomas Seoh, JD, EVP, Kitalys Institute, CEO, Kinexum

Keynote Lecture: Breakthroughs at the Tipping Point: The future of health, medicine, aging and longevity?

 Ken Dychtwald, PhD, Founder and CEO of Age Wave

Selected Scientific Topics in Aging: Longitudinal phenotypic markers of aging and other multidimensional prognostic approaches for age-related chronic diseases

Emerging evidence has uncovered a novel global longitudinal phenotypic metric of aging that is superior to phenotypic and epigenetic measurements and can facilitate the discovery of mechanisms underlying age-related chronic diseases. This session will discuss biological aging clocks and other multidimensional prognostic approaches that can be leveraged for the development of novel therapeutic targets. 


Luigi Ferrucci, MD, PhD, Scientific Director, National Institute on Aging 



Perry Kuo, PhD, Research Fellow – Longitudinal Studies Section, Clinical Research Branch, National Institute of Aging Intramural Research Program

Lenore Launer, PhD, Principal Investigator, Laboratory of Population Science and Epidemiology, National Institute on Aging Intramural Research Program

Eleanor Simonsick, PhD, Co-Director of the Baltimore Longitudinal Study of Aging, National Institute of Aging Intramural Research Program

Toshiko Tanaka, PhD, Staff Scientist, Longitudinal Studies Section, Clinical Research Branch, National Institute of Aging Intramural Research Program


Selected Scientific Topics in Aging: Mitochondria dysregulation and the integrated stress response in inflammaging and cellular senescence

Recent studies highlight a key role of dysregulated mitochondria in driving inflammaging and defective immunity. The integrated stress response (ISR), a key mechanism underlying the pathogenesis of neurodegenerative diseases, is being recognized as a novel player in cellular senescence. Join this session to discuss emerging evidence, including recent data on the impact of SARS-CoV-2, on the role of mitochondria bioenergetics on inflammatory responses and the effects of the ISS on the aging process.  


Luigi Ferrucci, MD, PhD, Scientific Director, National Institute on Aging 



Doug Wallace, PhD, Director of the Center for Mitochondrial and Epigenomic Medicine at Children's Hospital of Philadelphia, Michael and Charles Barnett Endowed Chair in Pediatric Mitochondrial Medicine and Metabolic Diseases, Children's Hospital of Philadelphia  


Hyung Don Ryoo, PhD, Professor, Department of Cell Biology New York University School of Medicine 


Achieving Evidence to Support Healthy Longevity Therapeutics & Products

One of the most often-cited challenges to the translation of advances in aging research into products that prevent chronic diseases and extend healthy longevity is the lack of a clear regulatory pathway. Join this session for a reflective consideration of what balance society may want to strike between risk-benefit, based on what levels of evidence, for interventions that target multiple diseases (or even pre-disease states) via different modalities like drugs, devices and foods/supplements.  What could proposed legislation look like, with appropriate incentives for innovation?


David Fox, JD, Partner, Hogan Lovells  

Alexander Fleming, MD, Founder and President of Kitalys Institute, Executive Chairman of Kinexum


Steven Austad, PhD, Professor in the Department of Biology at the University of Alabama at Birmingham, Senior Scientific Director, Interim Chair, Board of Directors, American Federation of Aging Research

Tom DiLenge, JD, Senior Partner, Global Public Policy, Regulatory & Governmental Strategy, Flagship Pioneering and former President, Advocacy, Law and Policy of BIO
Martin Hahn, JD, Partner, Hogan Lovells   

Ellis Unger, MD, Principal Drug Regulatory Expert, Hyman, Phelps & McNamara, P.C. and former Director, Office of Drug Evaluation-I, CDER, FDA

Identification and Adoption of Novel Biomarkers and Endpoints for Healthy Longevity Initiatives 

A major focus among those working in aging research and the preemption of chronic diseases is the identification of biomarkers. The field is intensively searching for biomarkers, surrogate markers and registrable endpoints that can lead to approval of therapeutic interventions without having to conduct impractically long, excessively large clinical trials.  Join this discussion of tractable efforts underway or under consideration by a roundtable of thought leaders. 


Steve K  Kritchevsky, PhD, Wake College, School of Medicine 


Shalender Bhasin, MB, Professor of Medicine, Brigham and Women's Hospital, Harvard Medical School 
Mark Espeland, PhD, Professor, Department of Internal Medicine, Wake Forest University School of Medicine

Anne Gingery, PhD, Assistant Professor Dept of Orthopedic Surgery, Mayo Clinic
Jamie Justice, PhD, Assistant Professor, Gerontology and Geriatric Medicine, Wake Forest University School of Medicine

George Kuchel, PhD, Professor of Medicine, UConn Center on Aging, University of Connecticut 

Joseph Menetski, PhD, Vice President at the Foundation of the National Institutes of Health 

Felipe Sierra, PhD, Chief Scientific Officer, Hevolution Foundation, former Director of Aging Biology, NIA

Tamar Tchkonia, PhD, Assistant Professor, Physiology and Biomedical Engineering, Mayo Clinic, Director of the Facility for Geroscience Network


What Should be the Elements for a National Policy on Healthy Longevity? 

What should be the elements for a National Policy on healthy longevity?  

Healthy Longevity, the extension of lifespan together with the expansion of healthspan (the period of life spent in good health), could potentially save trillions in healthcare costs and economic growth from an expanded market of healthy, active elderly.  Yet, the US, unlike some other parts of the globe, has no national policy on healthy longevity.  Join our panel of experts as they imagine what goals and elements – in research, clinical practice, regulatory framework, reimbursement and others – of such a national policy should be, informed by views in other countries. 

Thomas Seoh, EVP, The Kitalys Institute and CEO, Kinexum


Steven Austad, PhD, Professor in the Department of Biology at the University of Alabama at Birmingham, Senior Scientific Director, Interim Chair, Board of Directors, American Federation of Aging Research
John Beard, MD, ARC Centre of Excellence in Population Ageing Research, University of New South Wales
Nahid Bhadelia, MD, MALD, Senior Policy Advisor on Global COVID-19 Response, White House COVID-19 Response Team 
Evelyne Bischof, MD, MPH, FEFIM, Longevity physician at Human Longevity; Chief Associate Physician of Internal medicine at Renji Hospital of Jiaotong University School of Medicine; Associate Professor at Shanghai University of Medicine, China

Tom Kalil, Chief Innovation Officer, Schmidt Ventures, previously responsible for White House science and technology programs in the Obama and Clinton administrations

Adrienne Mendenhall, Global Business Development Lead, ACCESS Health International 

Tina Woods, Founder and CEO of Collider Health, Organizer and Moderator, UK Research and Innovation (UKRI)’s Healthy Ageing Industrial Strategy, Healthy Longevity Champion for the National Innovation Centre for Ageing 

David Fox, Partner, Hogan Lovells

'Honorable Mention' Poster Presentations

Alexander Klonoff, MD, MBA, Medical Consultant, Kinexum

Georgina Xanthou, PhD
, Adjunct Investigator, David Geffen School of Medicine, UCLA, Scientific Consultant, Kinexum 

Poster presenters will discuss their findings in 5 min “flash talks”, followed by a 2 min Q&A for each presentation. 

Kelvin Yen
, University of Southern California, Leonard Davis School of Gerontology
Kejun Ying, Brigham and Women's Hospital, Harvard Medical School
Lei Zhang, University of Minnesota
Huixun Du
, Buck Institute
Sam Collaudin, Cell Environment
Lihuan Guan, University of Melbourne


Day 2 | TUESDAY, OCTOBER 11, 2022 | 9:00AM - 7:15PM EDT

Welcome and Introduction to Day 2

Conference Co-Anchors: 
Alexander Fleming, MD, Founder and President, Kitalys Institute, Executive Chairman of Kinexum

Joan Mannick, MD, CEO, Tornado Therapeutics
Thomas Seoh, JD, EVP, Kitalys Institute, CEO, Kinexum

The COVID-19 Pandemic as of Year 3: the Birth of a New Chronic Disease

COVID-19 has affected nearly all aspects of our lives. Now, in the third year of the pandemic, continued investments in health, science, and disease surveillance are essential. Furthermore, we are witnessing the birth of a new chronic disease: long COVID. Leading academics and policymakers will discuss the next steps that governments must take to build resilient public health systems that can withstand current and future global health emergencies.



William Haseltine, PhD, Chair and President of ACCESS Health International; previously founder of multiple biotech companies, including Human Genome Sciences


Helen Clark, ONZ SSI PC, Former Prime Minister New Zealand, former head of United Nations Development Program  

Sandro Galea, MD, MPH, DrPH, Dean, Boston University, School of Public Health 

Margaret (Peggy) Hamburg, MD, Former FDA Commissioner  

Jeffrey Lehman, JD, Chancellor New York University of Shanghai, former President of Cornell University


The Importance of Research Collaborations in Confronting Medical Crisis: The Covid-19 Example

The Covid-19 pandemic has severely and disproportionately affected individuals with chronic diseases, from rising rates of diabetes to the birth of a new chronic disease: Long COVID. Join this session to discuss how using collaborative research models established during the COVID-19 pandemic can be adopted to address the pandemic of Long Covid and other chronic diseases. 


William Haseltine, PhD, Chair and President, ACCESS Health International 


George Daley, MD, Dean, Harvard Medical School
Clay Marsh, MD, Chancellor and Executive Dean, WVU Health Sciences
Roberto Patarca, MD, PhD, Chief Medical Officer, ACCESS Health International, Chronic Fatigue Syndrome expert
Lael Yonker, MD, Assistant Professor of Pediatrics, Massachusetts General Hospital


Leveraging Novel Immunological Signatures and Biological Pathways to Reverse Immunosenscence and Inflammaging

Inflammaging and immunosenescence play central roles in biological aging and contribute to increased susceptibility to infections. Join this session to learn about discoveries involving novel immune signatures/biological pathways in inflammaging, the intricate metabolic interactions between immune cells and adipocytes, and the effects of aging on anti-viral T cell immunity. 


Joan Mannick, MD, CEO, Tornado Therapeutics, USA 
Georgina Xanthou, PhD,
Adjunct Investigator, David Geffen School of Medicine, UCLA & Scientific Consultant, Kinexum 


David Furman, PhD, Director, Stanford 1000 Immunomes Project, Chief of the Center for AI and Data Science of Aging & Associate Professor, Buck Institute For Research on Aging 
Laura Haynes, PhD, Professor, Immunology, University of Connecticut, Center on Aging  
Tim Peterson, PhD, Assistant Professor in the Department of Medicine at Washington University St. Louis   

Paul Robbins, PhD, Professor of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota 

Targeting Root Causes of Neurodegeneration for Age-Related Chronic Diseases


Lawrence Steinman, PhD, MD, Professor of Neurology and Neurological Sciences, Pediatrics, and Genetics, Stanford University

Emerging evidence proposes early root causes of neurodegenerative diseases, including divergent and toxic protein conformations, hormone-like molecules and circulating factors that could be harnessed as novel therapeutic targets also for metabolic and autoimmune diseases. This session aims to illuminate common pathogenetic pathways that can be targeted, even in pre-disease states, to prevent and/or reverse age-related neurodegenerative and other chronic diseases.  


Georgina Xanthou, PhD, Adjunct Investigator, David Geffen School of Medicine, UCLA, Scientific Consultant, Kinexum 

Joan Mannick, MD, CEO, Tornado Therapeutics, USA 


Ted Dawson, MD, PhD, Professor of Neurology, Director, Institute for Cell Engineering, Johns Hopkins University
Peter De Keizer, PhD, Associate Professor, UMC Utrecht, Founder and Managing Director, Cleara Biotech B.V.

Mike Murphy, MD, PhD, Chief Medical and Scientific Officer, co-founder of Worldwide Clinical Trials
Jonathan Rothbard, PhD, Founder and CSO, 180 Life Sciences


American Federation for Aging Research (AFAR) Update on SuperAgers and FAST (biomarkers) Initiative

Nir Barzilai, MD, 
Professor, Department of Medicine (Endocrinology), Professor, Department of Genetics, Ingeborg and Ira Leon Rennert Chair in Aging Research, Director, Institute for Aging Research 

Sofiya Milman, MD, MS, Director, Human Longevity Studies, Associate Professor, Albert Einstein College of Medicine
John Beilinson, Communications Expert, American Federation for Aging Research (AFAR)


Jury Prize Winning Abstracts

Selected abstracts will be presented in the format of 10 min oral presentations followed by 5 min Q&A 

Jury Chairs:

Ana Maria Cuervo, PhD, Professor, Department of Developmental & Molecular Biology, Professor, Department of Medicine, Robert and Renée Belfer Chair for the Study of Neurodegenerative Diseases 

David Furman, PhD, Director of the Stanford 1000 Immunomes Project, Chief of the Center for AI and Data Science of Aging & Associate Professor, Buck Institute For Research on Aging


Day 3 | WEDNESDAY, OCTOBER 12, 2022 | 8:15AM - 6:00PM EDT

Welcome and Introduction to Day 3

Conference Co-Anchors: 
Alexander Fleming, MD, Founder and President, Kitalys Institute, Executive Chairman, Kinexum

Joan Mannick, MD, CEO, Tornado Therapeutics
Thomas Seoh, JD, EVP, Kitalys Institute, CEO, Kinexum

AI, Big Data and Devices for Healthy Longevity

It’s not just medicines and foods:  what roles are digital, ‘analog’ and diagnostic devices playing in the emerging longevity industry? 


Thomas Seoh, JD, EVP, Kitalys Institute, CEO, Kinexum 


Guruduth Banavar, PhD, CTO, Viome, former CTO, IBM and team leader on IBM Watson

Jessilyn Dunn, PhD, Assistant Professor and Director, BIG IDEAs Laboratory, Duke University 

Vadim N. Gladyshev, PhD, Professor of Medicine, Director, Center for Redox Medicine, Associate Member, Broad Institute, MIT  

Noosheen Hashemi, PhD, CEO, January AI 

Mike Snyder, PhD, Stanford W. Ascherman Professor in Genetics, Chair, Dept. of Genetics, Director, Center for Genomics and Personalized Medicine, Stanford University

Scientific Editors discuss advances and challenges in targeting underlying common roots of chronic diseases and enhancing health span

Editors from leading scientific journals in basic and translational biomedical research will discuss: (i) cutting edge studies targeting common roots of chronic diseases and infections, including metabolic, transcriptional and epigenetic reprogramming, and (ii) current challenges and opportunities to disseminate and educate specialists and the public on approaches targeting the prevention, rather than the cure, of chronic diseases. 

Michael Zemel, PhD, Chief Scientific Officer, Kinexum 


George Caputa, PhD, Senior Editor, Nature 

Rosalind Mott, PhD, Scientific Editor, Cell Metabolism 

Christoph Schmitt, PhD, Chief Editor, Nature Metabolism  


Commercialization: Who, What, How?

Who will fund the innovation necessary to achieve (or approach) healthy longevity for all?  What innovations should/will be funded?  How will such innovative products and services be reimbursed or paid for?  Join a roundtable of senior leaders in Big Pharma, Big Food, biotech, venture capital and other emerging sources of funding for a unique discussion across multiple domains on who may be the major players in the rapidly growing longevity industry.

Joe Cook,
Managing Director Mountain Group Partners; former COB/CEO of Amylin; former Group VP Global Operations, Eli Lilly

Dennis Purcell, Founder of Aisling Capital LLC, Joe Cook, Ed Saltzman, Executive Chairman of Cello Health BioConsulting 
Ed Saltzman, Head, Biotech Strategy, Lumanity, founder of Defined Health


Michael Baran, PhD, Executive Director, WRDM / Partner, Pfizer Venture Investments  
Morris Birnbaum, MD, PhD, Former Senior Vice President, Internal Medicine Research Unit, Pfizer 
Sebastian Aguiar Brunemeier, General Partner, Healthspan Capital, CEO, ImmuneAGE Bio, Co-Founder of Cambrian BioPharma and Samsara Therapeutics
Kevin L Duffin, MD, PhD, Associate Vice President and COO, Lilly Diabetes
Steven Gough, MD, SVP, Global CMO, Novo Nordisk

Joan Mannick, MD, CEO of Tornado Therapeutics
Antonio Tataranni, MD, Chief Medical Officer, PepsiCo 


Endogenous and Exogenous Ketosis in Health & Disease

Is a ketogenic diet good for health, resilience and performance?  Are there pills or supplements that can realize the benefits of ketosis without the high fat, low carb diet?  Emerging research suggests that endogenous and exogenous ketosis (ketosis induced by molecules naturally in the body, versus dosed from outside) can confer health benefits. Endogenous ketones are a preferred fuel with distinct metabolic advantages for both the central nervous system and the periphery. Exogenous ketones have been explored both in the context of healthspan and performance, including mild traumatic brain injury and cancer.


Ken Ford, PhD, Founder and CEO, Institute of Human and Machine Cognition (IHMC) 

Michael Zemel, PhD, Chief Scientific Officer, Kinexum 


Colin Champ, PhD, Associate Professor at Duke University Medical Center  
John Newman, PhD, Assistant Professor, Buck Institute for Research on Aging
Morley Stone, PhD, Chief Strategic Partnership Officer, IHMC 
Brianna Stubbs, PhD, Buck Institute for Research on Aging  

Jeff Volek, PhD, Professor, Department of Human Sciences, Ohio State University

Preempting Age-Related Chronic Diseases and Disabilities: How Do We Get There, Sooner than Later 

A wide spectrum of approved drugs and marketed nutritional products are proposed for targeting the biologic hallmarks of aging. The aim is to show a product’s safety and effectiveness for preempting multiple age-related chronic diseases and disability—and to do so sooner than later. The proposed session will examine major examples of assets ranging from nutrients to novel, unapproved pharmacologic agents, with repurposed approved drugs and their combinations in between.



Jay Skyler, MD, Professor of Medicine, Pediatrics, & Psychology, in the Division of Endocrinology Diabetes & Metabolism, Department of Medicine, University of Miami Leonard M. Miller School of Medicine  

Nir Barzilai, MD
, Professor, Department of Medicine (Endocrinology), Professor, Department of Genetics, Ingeborg and Ira Leon Rennert Chair in Aging Research, Director, Institute for Aging Research 
Joe Baur, PhD
, Professor of Physiology, Perelman School of Medicine, University of Pennsylvania 

Alexander Fleming, MD, Founder and President of Kitalys Institute, Executive Chairman of Kinexum

Steven Gough, MD, SVP, Global CMO, Novo Nordisk 
Catherine Kwik-Uribe, PhD, VP, Scientific and Regulatory Affairs, Applied Science and Nutrition, Mars Edge

Joan Mannick, MD, PhD CEO, Tornado Therapeutics
Hans-Juergen Woerle, MD, PhD
, Chief Scientific and Medical Officer, Nestle HealthScience 
Michael Zemel, PhD, Chief Scientific Officer, Kinexum

Concluding Remarks

Conference Co-Chairs: 
Alexander Fleming, MD, Founder and President, Kitalys Institute, Executive Chairman of Kinexum

Joan Mannick, MD, PhD CEO, Tornado Therapeutics

Thomas Seoh, JD, EVP, Kitalys Institute, CEO, Kinexum


Day 4 | THURSDAY, OCTOBER 13, 2022 | 9:00AM - 5:00PM EDT

in silico logo.png

Welcome and Introduction to Day 4 & The Kitalys Institute

A brief overview of the Kitalys Institute, which hosts the 'healthy longevity for all' community and resources for education, collaboration, and silo busting. 

Conference Co-Anchors: 
Alexander Fleming, MD, Founder and President, Kitalys Institute, Executive Chairman, Kinexum 
Thomas Seoh, JD, EVP, Kitalys Institute, CEO, Kinexum

Introductory Remarks on the Longevity Emerging Company Landscape 

Pepper Landson, Founder and CEO, Praetego
Phil Newman, CEO & Founder of Longevity.Technology
Dennis Purcell, Founder of Aisling Capital LLC

Thomas Seoh, JD, EVP, Kitalys Institute, CEO, Kinexum

Emerging Longevity Companies

9:30-10:00 | Cambrian Biopharma | Mark Nuttall, EVP Business Development

Cambrian BioPharma is building the medicines that will redefine healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health.

As a Distributed Development Company, Cambrian is advancing multiple scientific breakthroughs each targeting a biological driver of aging. Its approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve overall quality of life during aging. To date, Cambrian has more than a dozen novel therapeutics in development across its pipeline. For more information, please visit or follow us on Twitter @CambrianBio and LinkedIn.

10:00-10:30 | Amazentis SA | Anurag Singh, PhD, CMO
Amazentis is an innovative life science company dedicated to employing breakthrough research and clinical science to bring advanced therapeutic nutrition products to life.

10:30-11:00 | Life Biosciences | Jerry McLaughlin, PhD, CEO

Contrary to popular belief, aging is not caused by random wear and tear but instead is caused by a discrete set of biological mechanisms that can be targeted therapeutically.

We are pursuing a platform approach to develop therapeutics that can prevent, treat, and/or reverse multiple aging-related conditions. Each of our platforms is based on groundbreaking science from world-class researchers. We have exclusive licenses with leading academic institutions underpinned by strong composition-of-matter and method-of-use patents. We plan to initiate first-in-human studies for our first drug candidate in 2023.

11:00-11:30 | Viome | Guru Banavar, CTO

Our mission is to digitize, decode, and decipher human biology for the prevention, early diagnosis, and treatment of chronic diseases and cancer.


We are challenging the current medical-healthcare industrial paradigm that addresses how molecular phenomena are driving illness and disease.


Through the lens of a systems biology approach, we view health as a dynamic interplay between microbial and human gene expression.


11:30-12:00 | Insilico Medicine | Alex Zhavoronkov, PhD, CEO
Insilico Medicine, a pioneering artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques to discover novel targets and to design novel molecular structures with desired properties. Since 2021, Insilico has developed a growing portfolio in frontier areas including fibrosis, immunity, central nervous system (CNS) diseases and aging-related diseases empowered by its proprietary AI platform. Seven programs in its internal pipeline have progressed to the IND-enabling stage. It also successfully entered a Phase I clinical trial with its first AI-driven program targeting fibrosis.

12:00-12:45 | Lunch

12:45-1:00 | Cleara |  P.L.J. de (Peter) Keizer, PhD, Managing Director

Cleara is a biopharmaceutical R&D company dedicated to discovery and development of therapies against cancer and chronic diseases through selective elimination of subtypes of cellular senescence


Through detailed understanding of the molecular and biological pathways that underlie these individual pathological phenotypes, we set up disruptive, innovative and proprietary platform technology to design and optimize (peptide-based) therapeutics that exploit their weak spots for safe and selective clearance. Cleara’s lead FOXO4 program is focused on generation of disruptive and proprietary technology against “scarred” cellular senescence for treatment of metastatic, mutant-p53 cancer.


Senescent cells are associated with a range of chronic diseases and cancer progression. However, Cleara acknowledges that there are different kinds of senescence. We do not focus on “magic bullets” to kill all senescent cells but develop specific and safe compounds against unique subtypes. Cleara’s goal is to progress these into clinical development with the intent of precision medicine against specific diseases with clear niche-directed anti-senescence lead candidates, with associated biomarkers, around its FOXO4-based D-amino acid pipeline.


 Cleara is a private, Netherlands-based biotech company, tied with the University Medical Center Utrecht. Our scientific founders discovered that senescent cells impair tissue function and promote cancer metastases in mice (Cell, 2017; Cancer Discovery, 2016). Since then, we identified that what is called senescence is actually a collection of different phenotypes.

Cleara set up a platform that utilizes knowledge to design and optimize compounds against specific subtypes of senescence, thereby allowing for precise elimination of these in respective diseases.

1:00-1:15 | AdipoPharma | Vincent Marion, CEO

Harnessing the power of the Adipocyte for treatment of insulin resistance, type 2 diabetes

and associated comorbidities.

AdipoPharma SAS is committed to understanding the role of the adipocytes in diabetes via

their unique effect on lipid biosynthesis and management of whole-body lipid homeostasis.

The company was created to commercialize the work of its founder Dr. Vincent Marion PhD,

Msc, Biochemist and researcher at INSERM, the French National Institute for Health and

Medical Research. Dr. Marion’s team has spent more than a decade identifying therapeutic

targets based on the adipocyte’s specific role in the metabolic effects of insulin resistance

and diabetes. This work began by the detailed genetic investigation of Alstrom syndrome, an

ultra-rare devastating disease characterized by severe insulin resistance, early onset type 2

diabetes and associated metabolic dysfunctions. This led to the development of a detailed

analysis of the adipocyte’s complex function, its intrinsic lipid modulating effects and a

proprietary targeted approach to treatment. The result is AdipoPharma’s innovative first-inclass

therapeutic peptide “PATAS”, the first Adipeutic drug currently being developed for

clinical trials. This safe and novel therapeutic approach has been shown to restore healthy

lipid biosynthesis in the diseased adipocyte leading to reduction of nasty lipids like

ceramides. PATAS is set to be the first anti-diabetic drug to have a significant beneficial

effect on insulin resistance, beta cell plaque removal, liver steatosis and fibrosis and

ceramides, the leading cause of cardiovascular dysfunction in diabetes.

1:15-1:30 | Cerecin | Marc Cantillon, MD, CMO

A healthcare company with almost 20 years of innovation and leadership in brain health.

We develop novel evidence-based therapeutics and products that aim to help millions of people. These solutions are designed to target conditions ranging from memory impairment to Alzheimer’s disease and other devastating neurological diseases.


Cerecin is a global company headquartered in Singapore and the USA and our therapies are developed for persons around the world.

1:30-2:00 | VitaDao | Tim Peterson, PhD, Head of Research Portfolio | Laurence Ion, PhD, Longevity Dealflow Steward

VitaDAO is a decentralized collective funding longevity research & drug discovery.

"We fund early-stage research and spin out assets and newcos with industry partners and VCs.


Members join VitaDAO by purchasing VITA tokens or earning them through contributions of work or intellectual property.

We are a rapidly scaling collaborative network of expertise -- our goal is to change how science is funded and translated into new medicines"

2:00-2:15 | ImmuneAGE Pharma | Sebastian Brunemeier, CEO & Founder of ImmuneAGE Pharma and Co-Founder of Healthspan Capital

ImmuneAGE Pharma is a drug discovery platform for immune system rejuvenation. The company is focused on ex vivo and in vivo rejuvenation of hematopoietic stem cells (HSCs) with labs in Oxford and Switzerland. 

2:15-2:30 | Elevian | Mark Allen, PhD, CEO

At Elevian, we are developing new medicines that promote recovery and regeneration.

Our lead program is a recombinant protein for the treatment of stroke in the days following the event, for which there are currently no viable treatments.

By promoting regeneration, Elevian’s medicines have the potential to treat and prevent many aging-associated diseases.

2:30-2:45 | Oviva Therapeutics | Daisy Robinton, PhD, CEO & Co-Founder
Oviva is a premier biotech company developing first-in-class therapeutics to improve ovarian function and consequently extend female healthspan. Oviva is leading a movement to improve women’s experiences of aging through biomedical research, clinical development and advocacy. While driving tangible progress through therapeutics programs, Oviva is engaging with scientists, clinicians, policy makers and the general public to elevate, and equalize, the conversation around women’s health. In bringing together stakeholders across disciplines, we are inviting diverse perspectives and skill sets to drive innovation and progress in this space.

2:45-3:00 | Deciduous TherapeuticsAnil Bhushan, PhD, Professor, University of California, San Francisco & Scientific Founder of Deciduous Therapeutics

Deciduous Therapeutics aims to positively impact human health span through the development of novel medicines that activate the endogenous immune mechanism responsible for the elimination of senescent cells.

Senescent cells, which are characterized by irreversible damage and an inflammatory secretome, are considered a key driving force behind many age-related diseases. Due to a failure in immune surveillance, senescent cells accumulate and impact their local environment by inducing inflammation and promoting extracellular matrix remodeling, thus resulting in a myriad of metabolic and fibrotic consequences. Therefore, enabling the removal of senescent cells dramatically ameliorates disease pathologies in many age-related diseases, leading to overall improvements in health-span.

At Deciduous Therapeutics, we have discovered novel molecules that can activate a critical endogenous immune surveillance mechanism to selectively remove senescent cells and thereby treat several classes of age-related diseases.

3:00-3:15 | Enterin | Michael Zasloff, MD, PhD, Co-Founder, CSO, and Board Member/Denise Barbut, MD, FRCP, Co-Founder, President, CMO, and Board Member

We are a clinical stage biopharmaceutical company pioneering novel treatments that target the gut-brain axis and modify the course of neurodegenerative disorders. Our research has aided the scientific community in understanding the link between infection and the role of the enteric nervous system (ENS) in immune defense. As a result of repeated insults to the gastrointestinal tract (GIT), neural communication between the ENS and the central nervous system (CNS) is progressively impaired. Our work has clarified the relationship between immune defense, the ageing process, and progression of neurodegeneration.

We are now leveraging these years of research to become the first company in the world to develop pharmacologic interventions that repair the ENS and the dysfunctional gut-brain axis in patients with neurodegenerative diseases. Our lead compound, ENT-01, displaces membrane-bound alpha-synuclein (αS) aggregates from enteric nerve cells and improves neural signaling between the gut and the brain as demonstrated in animal models of Parkinson’s Disease. In clinical trials involving patients with Parkinson’s Disease, we have shown improvement in non-motor symptoms, such as hallucinations, dementia, sleep/Rem Behavior Disorder and constipation, as well as improvement in motor symptoms. Unexpectedly, we found dose-dependent normalization of circadian rhythm, which is intimately linked to sleep, dementia, and hallucinations. Our second compound, ENT-03, reverses central insulin resistance and is being developed for the treatment of obesity, type 2 diabetes, and Alzheimer’s Disease.

Our long-term vision is that these discoveries and our ongoing research will help us understand how to delay the ageing process, prevent neurodegeneration, and eventually prolong the lifespan of patients with these diseases.

3:15-3:30 | Pano Therapeutics | Ben Gibson, CEO, Francesca Fieni, PhD, CSO/Co-Founder, Ken Batchelor, PhD, Head of Research & Development
Pano is a drug discovery and development platform company focused on the clinical development of small molecule drugs targeting Mitochondrial Complex I.  Pano was founded on the basis of the discovery of a novel drug target - mtTOB, ‘Mitochondrial Target of Biguanides’ - associated with Mitochondrial Complex I, that enables the first rational drug discovery of biguanides and other classes of Complex I / mtTOB modulators. Pano’s drug discovery and development platform has been designed to generate novel drug candidates with therapeutic efficacy and safety for a range of indications. Pano is initially advancing preclinical assets based upon selected and patented lead compound candidates for rare and high prevalence kidney diseases.

3:30-3:45 | January AI | Noosheen Hashemi, CEO
Founded by veteran business executive, Noosheen Hashemi, and Director of Genomics and Personalized Medicine at Stanford University, Dr. Michael Snyder, January AI is the first "precision health" company to utilize powerful AI technology to predict how a person's body responds to food and activity. January leverages heart rate and glucose data to align a user’s health habits in precisely the way their body needs. However, January remains the only product on the market where a CGM (continuous glucose monitor) is not required after an initial training period; once the user has trained the AI, January will then continue to provide glucose estimates and insights on an ongoing basis, allow a user to predict their glucose curve 2 hours into the future, and see how a specific food or beverage would impact their body before they eat it — all without having to wear a CGM.


3:45-4:00 | Oisin | Matthew Scholz, PhD, CEO

In Celtic myth, Oisín (sometimes Ossian) was the Gælic warrior-bard of the 7th century who sought the land of youth – a magical island off the western coast of Ireland.  Today Oisín Biotechnologies is working to make the myth a reality.


Oisín Biotechnologies' ground-breaking research and technology is demonstrating that the solution to mitigating the effects of age-related diseases is to address the damage created by the aging process itself.  We invite you to see how.

Our First Target - Senescent Cells

When cells detect that they have been irreversibly damaged, they enter a non-dividing condition known as cell-cycle arrest, or senescence.

It’s believed this occurs to prevent cells from going rogue and turning cancerous. Ideally, they should die by the process known as apoptosis, but as we age, more and more frequently they don’t. They become zombie cells – unable to kill themselves or resume normal function.

Senescent cells secrete molecules that cause inflammation in an effort to attract immune cells that would usually clear them. But for reasons that are not fully known, as we age, persistently senescent cells accumulate, leading to a vast number of age-related diseases.

Oisín is developing a highly precise, patent-pending, DNA-targeted intervention to clear these cells. As a recent study has shown, clearing senescent cells both reduces negative effects of aging pathologies and also extends median lifespan and survival.*

* Baker, Darren J., et al. "Naturally occurring p16Ink4a-positive cells shorten healthy lifespan." Nature 1038.16932 (2016)

4:00-4:15 | Rivus Pharmaceuticals, Allen Cunningham, President and CEO

Rivus Pharmaceuticals, a leader in mitochondrial biology, is advancing a new class of medicines designed to address a primary driver of cardio-metabolic diseases: obesity.


Harnessing the natural process of mitochondrial uncoupling, Rivus’ Controlled Metabolic Accelerators (CMAs) provide a new, measured approach to reducing fat throughout the body. By doing so, CMAs can reduce the risk of cardio-metabolic disease with the aim of enabling healthier lives for millions.


Addressing a primary driver of cardio-metabolic disease: obesity 

Nearly half of American adults are living with cardio-metabolic diseases. While numerous factors contribute to these diseases, a common thread driving pathology is obesity, the result of excess fat in the body. Associated with an elevated risk of heart failure, type 2 diabetes, dyslipidemia, NAFLD/NASH and other indications, obesity presents an opportunity to target a significant risk factor for cardio-metabolic disease. Newer therapies support weight loss but may also reduce lean muscle mass, which can lead to weight regain and increased cardiovascular risk.


Harnessing a natural metabolic process for fat selective weight loss

Rivus is advancing a new class of therapies called Controlled Metabolic Accelerators (CMAs), designed to selectively reduce excess fat by leveraging mitochondrial uncoupling. Mitochondrial uncoupling is a natural metabolic process that accounts for approximately 20-40% of caloric consumption and significantly contributes to basal metabolic rate. Rivus’ CMAs provide a novel, measured approach to activating this process, reducing fat throughout the body while preserving skeletal muscle mass.



CMAs have the potential to provide well-tolerated, effective treatments that improve cardio-metabolic health with applicability to a broad range of diseases.


Clinical research demonstrates the potential of Rivus’ lead candidate HU6, a first-in-class CMA, to address a broad range of cardio-metabolic diseases by increasing fat selective weight loss and improving key markers of glycemic control and inflammation. Importantly, no loss of lean muscle mass has been observed, suggesting reduced risk of weight regain and reduced cardiovascular risk.


For its lead program HU6, Rivus Pharmaceuticals has completed Phase 1 clinical studies and a Phase 2a metabolic study. Building on data from the metabolic study, Rivus recently initiated a Phase 2a study in obese participants with heart failure with preserved ejection fraction (HFpEF) and plans to initiate a Phase 2b study in obesity, including a subset of obese participants with type 2 diabetes in 2023. Rivus is expanding the therapeutic utility of mitochondrial uncoupling with new CMAs targeting a myriad of diseases where preclinical evidence for safe metabolic acceleration is strong and the therapeutic need is great.


Cambrian logo.png
life logo.png
viome logo.png
cleara logo.jpg
ImmuneAge Logo 1.png
cerecin logo.png
vitadao logo.png
oviva logo 1.png
deciduous logo.jpg
Pano logo.jpg
january ai logo.png
enterin logo.jpg
amazentis logo 1.jfif
adipopharma logo.jpg
oisin logo.png

The distinct ‘lane’ of Metabesity is seeking to accelerate the translation of emerging science into material, accessible gains in public health, through the prevention or delay of chronic diseases and the extension of healthy longevity.  Thus, the conference has not been just among scientists, or clinical trialists, or companies and funders, but a conference conversation among leaders from a range of disciplines needed to achieve this aim.

Metabesity 2022 will feature a number of distinguished invited speakers who are experts in many fields. We prize interdisciplinary, ‘silo-busting’ sessions, going so far as to characterize the conference model as a dinner salon rather than a series of lectures. Our speakers come from multiple disciplines, and our panels are formed for lively interaction between experts that rarely dialog with each other.

Please email with any suggestions you have for sessions you would like to see Metabesity 2022!

bottom of page